This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO (AVRO) Resumen de Acciones

AVROBIO, Inc. es una empresa de terapia génica en fase clínica que desarrolla terapias génicas con células madre hematopoyéticas para tratar enfermedades raras en Estados Unidos. Saber más

Análisis fundamental de AVRO
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	0/6
Rendimiento pasado	3/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

El ratio precio-beneficio (24.9x) es inferior a la media de la industria Biotechs (16.2x)

Ha pasado a ser rentable este año

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Se prevé que los beneficios disminuyan un promedio de 18.4% al año durante los próximos 3 años

Grandes partidas extraordinarias que afectan a los resultados financieros

No tiene una capitalización de mercado significativa ($64M)

AVRO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de AVROBIO, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del AVROBIO
Precios históricos de las acciones
Precio actual de la acción	US$16.80
Máximo en las últimas 52 semanas	US$19.80
Mínimo de 52 semanas	US$10.56
Beta	1.22
Cambio en 1 mes	1.45%
Variación en 3 meses	9.38%
Cambio de 1 año	44.82%
Variación en 3 años	-85.45%
Variación en 5 años	-90.89%
Variación desde la OPV	-95.51%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Oct 18

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-02 to treat Gaucher disease. The Innovation Passport is the first step in the ILAP process for regulatory and development milestones with the aim of early patient access in the U.K., the company said in a statement on Tuesday. Avrobio's noted that AVR-RD-02 has previously received fast track status in the U.S. and orphan drug designations in the U.S. and EU. Gaucher disease is a rare lysosomal disorder caused by buildup of certain fatty substances in organs, mainly the in the spleen and liver. AVRO +8.65% to $0.66 premarket Oct. 18

Seeking Alpha • Sep 20

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-04 to treat cystinosis. Cystinosis is a rare, multisystem genetic disorder characterized by the excess build up of an amino acid called cystine in different tissues and organs, with the most affected being the kidneys, and eyes. This can damage the kidneys and can progress to end-stage kidney disease. AVR-RD-04 is designed to genetically modify patients' own hematopoietic stem cells (HSCs) to express the gene encoding cystinosin, the protein which is deficient in people living with cystinosis, the company said in a Sept. 20 press release. Avrobio added that AVR-RD-04 is the first gene therapy in development for cystinosis. AVRO +6.25% to $0.85 premarket Sept. 20

Seeking Alpha • Jul 13

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

The shares of gene therapy company AVROBIO (NASDAQ:AVRO) jumped ~9% in the pre-market Monday after the company announced that the FDA awarded the orphan drug designation for AVR-RD-05, a gene therapy candidate for mucopolysaccharidosis type II (MPSII), or Hunter syndrome. MPSII belong to a group of inherited metabolic disorders collectively called mucopolysaccharidosis. The rare lysosomal disorder primarily affects young boys. With its orphan drug designation, the FDA aims to offer financial incentives to drug developers targeting rare diseases and conditions. In addition to tax credits for clinical trial costs and waiver of the user fee for marketing applications, the developers of orphan drugs can claim seven years of marketing exclusivity upon regulatory approval of the treatment. In 2023, AVROBIO (AVRO) plans to start a Phase 1/2 clinical trial for Hunter syndrome in collaboration with the University of Manchester, UK.

Artículo de análisis • Nov 13

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Artículo de análisis • Aug 10

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Artículo de análisis • Mar 08

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Artículo de análisis • Nov 23

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rentabilidad de los accionistas

	AVRO	US Biotechs	Mercado US
7D	-4.8%	2.4%	1.1%
1Y	44.8%	34.6%	28.7%

Rentabilidad vs. Industria: AVRO superó a la industria US Biotechs, que obtuvo un rendimiento del 34.6% el año pasado.

Rentabilidad vs. Mercado: AVRO superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.

Volatilidad de los precios

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: AVRO no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AVRO (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. es una empresa de terapia génica en fase clínica que desarrolla terapias génicas con células madre hematopoyéticas para tratar enfermedades raras en Estados Unidos. Sus terapias génicas emplean células madre hematopoyéticas extraídas del paciente y modificadas con un vector lentiviral para insertar el equivalente de una copia funcional del gen mutado en la enfermedad diana. La cartera de productos de la empresa incluye AVR-RD-02, que se encuentra en ensayos clínicos de fase 1/2 para el tratamiento de la enfermedad de Gaucher tipo 1 y 3; AVR-RD-01, que se encuentra en ensayos clínicos de fase 2 para el tratamiento de la enfermedad de Fabry; y AVR-RD-03 que está en fase preclínica para el tratamiento de la enfermedad de Pompe.

Resumen de fundamentos de AVROBIO, Inc.

¿Cómo se comparan los beneficios e ingresos de AVROBIO con su capitalización de mercado?
Estadísticas fundamentales de AVRO
Capitalización bursátil	US$63.75m
Beneficios(TTM)	US$30.31m
Ingresos (TTM)	n/a

24.9x

Ratio precio-beneficio (PE)

0.0x

Ratio precio-ventas (PS)

¿Está AVRO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AVRO
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	-US$30.31m
Beneficios	US$30.31m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.68
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado AVRO a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2024/06/20 02:04
Precio de las acciones al final del día	2024/06/20 00:00
Beneficios	2024/03/31
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

AVROBIO, Inc. está cubierta por 15 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Yun Zhong	Brean Capital Historical (Janney Montgomery)
Yun Zhong	BTIG
Whitney Ijem	Guggenheim Securities, LLC

This company is no longer active

AVROBIO (AVRO) Resumen de Acciones

Recompensas

Análisis de riesgos

Competidores de AVROBIO, Inc.

Spero Therapeutics

Eagle Pharmaceuticals

Protalix BioTherapeutics

CytomX Therapeutics

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de AVROBIO, Inc.

Beneficios e Ingresos